PMID- 19667604
OWN - NLM
STAT- MEDLINE
DCOM- 20090901
LR  - 20181201
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 112
IP  - 5 Suppl Unanswered
DP  - 2002 Nov
TI  - Consistency of ss-blocker effect across various subgroups with heart failure: 
      insights from the MERIT-HF trial.
PG  - 16-23
LID - 10.3810/pgm.11.2002.suppl22.116 [doi]
AB  - Several recently completed survival trials, including Metoprolol CR/XL Randomized 
      Intervention Trial in Congestive Heart Failure (MERIT-HF), Cardiac Insufficiency 
      Bisoprolol Study II (CIBIS-II), and the Carvedilol Prospective Randomized 
      Cumulative Survival (COPERNICUS) trial have examined the effects of ss-blockers 
      on survival and the need for hospitalization. The results from these trials are 
      remarkably consistent regarding reduction of both mortality and hospitalizations 
      for worsening heart failure. MERIT-HF investigated the effect of the lipophilic 
      ss-blocker extended-release metoprolol succinate given once daily in addition to 
      optimum standard therapy in patients with New York Heart Association (NYHA) 
      functional classes II through IV chronic heart failure and ejection fractions of 
      40% or below. The aim of this article is to review the consistency of ss-blocker 
      effect across various predefined risk groups as well as some post hoc subgroups 
      in MERIT-HF.
FAU - Wikstrand, John
AU  - Wikstrand J
AD  - Sahlgrenska University Hospital, SE 413 45 Goteborg, Sweden. 
      john.wikstrand@wlab.gu.se
FAU - Ghali, Jalal K
AU  - Ghali JK
FAU - Goldstein, Sydney
AU  - Goldstein S
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Carbazoles)
RN  - 0 (Propanolamines)
RN  - 0K47UL67F2 (Carvedilol)
RN  - GEB06NHM23 (Metoprolol)
SB  - IM
MH  - Adrenergic beta-Antagonists/*therapeutic use
MH  - Antihypertensive Agents/therapeutic use
MH  - Carbazoles/therapeutic use
MH  - Carvedilol
MH  - Heart Failure/*drug therapy/epidemiology/mortality
MH  - Humans
MH  - Metoprolol/therapeutic use
MH  - Propanolamines/therapeutic use
MH  - Risk
MH  - Treatment Outcome
MH  - United States/epidemiology
RF  - 13
EDAT- 2002/11/01 00:00
MHDA- 2009/09/02 06:00
CRDT- 2009/08/12 09:00
PHST- 2009/08/12 09:00 [entrez]
PHST- 2002/11/01 00:00 [pubmed]
PHST- 2009/09/02 06:00 [medline]
AID - 10.3810/pgm.11.2002.suppl22.116 [doi]
PST - ppublish
SO  - Postgrad Med. 2002 Nov;112(5 Suppl Unanswered):16-23. doi: 
      10.3810/pgm.11.2002.suppl22.116.